GSK Retained Earnings (Accumulated Deficit) 2010-2024 | GSK

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

GSK retained earnings (accumulated deficit) for 2024 were $9.963B, a 10.64% increase from 2023.
GSK retained earnings (accumulated deficit) for 2023 were $9.005B, a 66.86% increase from 2022.
GSK retained earnings (accumulated deficit) for 2022 were $5.397B, a 50.6% decline from 2021.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

GSK retained earnings (accumulated deficit) for 2024 were $9.963B, a 10.64% increase from 2023.
GSK retained earnings (accumulated deficit) for 2023 were $9.005B, a 66.86% increase from 2022.
GSK retained earnings (accumulated deficit) for 2022 were $5.397B, a 50.6% decline from 2021.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$228.9B
Amgen (AMGN)	$158.1B
Gilead Sciences (GILD)	$134.2B
Vertex Pharmaceuticals (VRTX)	$121.1B
Bristol Myers Squibb (BMY)	$111.6B
CSL (CSLLY)	$80.7B
Regeneron Pharmaceuticals (REGN)	$75B
Argenex SE (ARGX)	$38.9B
Alnylam Pharmaceuticals (ALNY)	$32.4B
BioNTech SE (BNTX)	$28.7B
BeiGene (ONC)	$23.2B
Biogen (BIIB)	$20B
Illumina (ILMN)	$16.3B
Insmed (INSM)	$15B
Genmab (GMAB)	$14.5B
Genmab (GNMSF)	$14.4B
Moderna (MRNA)	$13.8B
Intra-Cellular Therapies (ITCI)	$13.7B
Incyte (INCY)	$13.6B
BioMarin Pharmaceutical (BMRN)	$12.5B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Bio-Techne Corp (TECH)	$10.4B
Vaxcyte (PCVX)	$10.4B
Sarepta Therapeutics (SRPT)	$10.2B
Exelixis (EXEL)	$9.8B
Ascendis Pharma (ASND)	$9.4B
Exact Sciences (EXAS)	$9.3B
Bio-Rad Laboratories (BIO.B)	$8.7B
QIAGEN (QGEN)	$8.7B
Repligen (RGEN)	$8.4B